CatalystWireBeta

UK small-cap RNS · 24 Feb 2026

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 14:32
    Holding(s) in Company Holding
  2. 07:00
    Contract win
    A £75,000 upsell on a sensitive government cyber programme that has already yielded over £250,000 adds revenue to the turnaround. It is small against £2.1m annual revenue, and the Sopra Steria partnership is only potential.
    Turnaround plan with targets £0.1m · 1% of mcap3 new orders in 3 months – usually about 1 +5.9% on the day
    Moved: Cost-led turnaround to profit: Turnaround continuing; contract wins adding to revenue → Turnaround continuing; further contract win
  3. 07:00
    Holding(s) in Company Holding
  4. 07:00
    Final Results Results
    These are the final FY25 results, not a new warning. The slump was flagged earlier, and the adjusted loss of £1.6m is slightly above the £1.5m expected. Against that, £4.5m of FY26 sales is now firm.
    Transformational contract / build-out £4.1m · 91% of mcapbelow expectationsoutlook mixedfirst in 8 months −12.8% on the day
    Moved: Post-SDR contract and framework pipeline: Accepted as Aurora Evolve Specialist Provider → Order book rebuilding; £4.5m FY26 sales firm · Procure X marketplace build-out: Awaiting fundraise completion to accelerate development → Funded; development continuing · Fundraising and general meeting: Retail Offer open; shareholder approval pending → Completed; £2.1m net raised (closed)
  5. 07:00
    Half-year Results Results
    Company only expects full-year 2026 performance 'in line with market expectations' and confirms medium-term targets; this is a confirmation, not a guidance raise.
    Segment turn in lineoutlook positivefirst since Oct 2023 −3.3% on the day
    Moved: Reignite Growth strategy: First net inflow quarter since FY 2023 → Half-year net inflows; investing ahead of growth
  6. 07:00
    Trading Update Trading update
    Year-end update confirms eight new investments, £30.7m of disposal proceeds and £13.0m of dividends intended for FY2027, which lifts the earlier minimum of £5.0m. Group funds fell to £49.5m as cash was deployed.
    Capital return £30.7m · 13% of mcapoutlook positive +3.7% on the day
    Moved: Deploying cash into new investments: New £5.3m Sodalis investment made → Eight new investments done; nine under assessment
  7. 07:00
    Corporate Update
    Pristine Capital Plc / EPIC: PRIS / Market: LSE
    Balance-sheet stress / refinancing outlook negative +0.0% on the day
    Moved: Funding and legal action: Reviewing finances; listing suspended → Abort fees unsettled; equity raise needed; deadline likely missed
  8. 07:00
    Final Results Results
    FY25 NAV per share up 61.2% to GEL 154.68, driven by Lion Finance Group's share price and large private portfolio companies' EBITDA growth; the NCC ratio fell to a record low 2.3%, de-risking the balance sheet.
    Capital return outlook positive +2.2% on the day
    Moved: GEL 700m capital return programme: US$50m tranche under way; programme runs to end-2027 → US$50m tranche completed; new US$50m launched · Gormed hospital acquisition: Agreed 25 Oct 2025, pending regulatory approval → Completed; consolidated from December 2025 (closed)
  9. 07:00
    Q3 Trading Update: EBITDA guidance Upgrade Trading update
    Adjusted EBITDA guidance is lifted to not less than £7m from £6-7m, so the previous top of the range becomes the floor. Net debt guidance is confirmed below £6m.
    Turnaround plan with targets £110.0m · 122% of mcapahead of expectationsoutlook positive, raised +6.6% on the day
    Moved: Three-year turnaround plan: Growth wins building: NHS England, DEFRA, HMLR → Turnaround concluded; new growth phase next (closed) · new: Next three-year growth plan – FY27 budget being finalised

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note